IRCT20200825048515N70 IRCT 2023-09-06 Esfahan University of Medical Sciences Comparative study of treatment results of different chemotherapy in patients with lymphoma cancer Comparative study of the therapeutic results of Carboplatin, Etoposide, ARAC, Melfalan chemotherapy regimes with CCNU, Etoposide, ARAC, Melfalan diet as a diet before autologous stem cell transplantation in patients with resistant / recurrent lymphoma 2023-07-21 anticipated 44 Complete https://irct.ir/trial/70686 interventional Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 2 Condition 1: Hodgkin lymphoma. Condition 2: Non Hodgkin lymphoma. Intervention 1: First intervention group: First, the patient undergoes mobilization (stimulation of stem cells to move from the BM side to the peripheral blood by means of GCSF medicine). Then stem cells are separated from peripheral blood by OPTIA device with apheresis technique. At this stage, the patient is being treated with heavy conditioning chemotherapy including Etoposide 300 mg/m2 (2 to 3 days), ARAC 300 mg/m2 (2 to 3 days), Melphalan 140 mg/m2 (1 day). and Carboplatin 750 mg/m2 (2 to 3 days) is placed. Intervention 2: Second intervention group: First, the patient undergoes mobilization (stimulation of stem cells to move from the BM to the peripheral blood by means of GCSF). Then stem cells are separated from peripheral blood by OPTIA device with apheresis technique. At this stage, the patient is being treated with heavy conditioning chemotherapy including Etoposide 300 mg/m2 (2 to 3 days), ARAC 300 mg/m2 (2 to 3 days), Melphalan 140 mg/m2 (1 day). and CCNU is placed at 200 mg/m2 (4 days). No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information